SLAM Biotherapeutics

A Unique Approach To Blood Cancer Therapeutics

About this Event

While advances have been made treating blood cancers, challenges remain, and several including acute myeloid leukemia and cutaneous T-cell lymphoma are still incurable. In addition, chemotherapy which is traditionally used to treat these cancers can be highly toxic and carry significant side effects.

That could be changing,however, thanks to the work of clinicians and scientists like Dr. Steven T. Rosen. A giant in the cancer community, Dr. Rosen is the SAB Chair and co-founder of SLAM Biotherapeutics.

SLAM Biotherapeutics is an oncology biotech company developing first-in-class antibodies and antibody drug conjugates (ADCs) that meet this challenge with strong efficacy and a safe tox profile. Their breakthrough antibodies will impact the lives of patients with life-threatening cancers. SLAM Bio is targeting CD84 which is a member of the signaling lymphocytic activation molecule (SLAM) protein family and expressed by a wide range of blood cancers and immune suppressor cells in all cancers.

SLAM Bio has a broad IP portfolio of 17 antibodies targeting CD84 with issued patents and an exclusive license from City of Hope and The Weizmann Institute. Their lead program is a first-in-class antibody targeting CD84, a cell surface adhesion molecule that is expressed on a spectrum of blood cancers and on immune suppressor cells in the micro-environment of all cancers. Phase I clinical trials will be initiated in the first half of 2026, a major inflection point for this drug targeting a $20+ billion market.

Sign up today to watch our Fireside Chat with Dr. Rosen, Rick Heinick, SLAM Bio Chairman and Co-Founder, and CEO, Steve Potts. They will discuss the latest developments in their quest to eradicate the deadly blood cancers and provide hope to millions of people worldwide.

Video On Demand

– Recorded

March 10

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.